6200 Lookout Road
72 articles with miRagen Therapeutics
New Year, fresh start? Could be. WalletHub recently compared more than 180 cities across the U.S., using 30 key indicators to evaluate their job strength. Some of those factors were job opportunities, employment growth, monthly average starting salary and employment outlook.
There’s been another milestone in the history of biotech: The world’s first RNAi gene-silencing drug, Alnylam Pharmaceuticals’ Onpattro, got approved on August 10. That makes 2018 a landmark year. But another year—2014—may prove just as influential for the field and how it develops.
8/3/2018Navitor Pharmaceuticals, headquartered in Cambridge, Massachusetts, announced that Thomas E. Hughes will be the company’s new chief executive officer.
In addition, the Company has granted the underwriters a 30-day option to purchase up to an additional 1,050,000 shares of common stock on the same terms and conditions.
All of the common stock is being offered by miRagen
miRagen Therapeutics Presents New Data from Phase I Clinical Trial of MRG-106 in Mycosis Fungoides at the T-Cell Lymphoma Forum
The data will be presented today, February 2, 2018, at the 10th Annual T-cell Lymphoma Forum in La Jolla, California.
Leah Rush Cann, an analyst with Oppenheimer, launched coverage of this biotech citing the possibility it could exceed $1.2B in revenue by 2025.
Her appointment increases miRagen’s Board from seven directors to eight directors.
miRagen Therapeutics Presents New Interim Clinical Data Expanding on Previous Data Suggesting Positive Impact From Systemically Administered MRG-106 on Mycosis Fungoides Form of Cutaneous T-Cell Lymphoma
The data are being presented at the 2017 American Society of Hematology (ASH) Annual Meeting in Atlanta, Georgia, by Christiane Querfeld, M.D., Ph.D., Chief of the Division of Dermatology, and Director, Cutaneous Lymphoma Program at the City of Hope in Duarte, California.
Revenue was $1.6 million for the third quarter of 2017, compared to $0.9 million for the third quarter of the prior year.
miRagen Presents New Clinical Data Suggesting Positive Impact From Systemically Administered MRG-106 On Mycosis Fungoides Form Of Cutaneous T-Cell Lymphoma At EORTC Global Task Force Meeting
miRagen Presents New MRG-201 Preclinical Data For Inhaled Microrna-29 Mimic Targeting Pulmonary Fibrosis
miRagen To Announce Second Quarter 2017 Financial Results And Host Webcast Conference Call On August 11, 2017
miRagen To Present MRG-106 Phase I Clinical Trial Data At The International Conference On Malignant Lymphoma
miRagen Receives EU Orphan Medicinal Product Designation For MRG-106 For The Treatment Of Cutaneous T-Cell Lymphoma
miRagen To Present New Clinical Trial Data For MRG-106, An Oligonucleotide Therapeutic Targeting Microrna-155, At The ASCO Annual Meeting
Servier And miRagen Extend Collaboration For The Research, Development And Commercialization Of Microrna-Targeting Therapeutics